Latest Ratios: P/E Ratio 414.5x · EV/EBITDA 269.8x · ROE 2435.0%. (2022–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Market Cap | $445M | — | — | — |
| Enterprise Value | $446M | — | — | — |
| P/E Ratio → | 414.55 | — | — | — |
| P/S Ratio | 71.60 | — | — | — |
| P/B Ratio | 9999.00 | — | — | — |
| P/FCF | 3219.65 | — | — | — |
| P/OCF | 1045.99 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | 269.80 | — | — | — |
| EV / EBIT | 320.98 | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Gross Margin | 67.2% | 67.2% | 65.1% | 42.3% |
| Operating Margin | 22.3% | 22.3% | 16.8% | -14.8% |
| Net Profit Margin | 19.3% | 19.3% | 12.9% | -8.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ROE | 2435.0% | 2435.0% | — | — |
| ROA | 23.4% | 23.4% | 13.8% | -4.8% |
| ROIC | 265.0% | 265.0% | — | — |
| ROCE | 341.0% | 341.0% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Debt / Equity | 23.57 | 23.57 | — | — |
| Debt / EBITDA | 0.70 | 0.70 | 0.69 | — |
| Net Debt / Equity | — | 6.98 | — | — |
| Net Debt / EBITDA | 0.21 | 0.21 | -0.82 | — |
| Debt / FCF | — | 2.49 | -13.47 | -0.07 |
| Interest Coverage | 66.54 | 66.54 | 38.73 | -25.73 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Current Ratio | 0.68 | 0.68 | 0.62 | 0.57 |
| Quick Ratio | 0.68 | 0.68 | 0.62 | 0.57 |
| Cash Ratio | 0.56 | 0.56 | 0.36 | 0.27 |
| Asset Turnover | — | 1.16 | 1.23 | 0.55 |
| Inventory Turnover | 76.18 | 76.18 | 74.65 | 30.71 |
| Days Sales Outstanding | — | 33.97 | 93.18 | 219.61 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Earnings Yield | 0.2% | — | — | — |
| FCF Yield | 0.0% | — | — | — |
| Buyback Yield | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — |
| Shares Outstanding | — | $17M | $17M | $17M |
Demographic and geographic concentration
Based on current market data, MCTA trades at a P/E of 414.55 and a P/S of 71.60, suggesting that investors are pricing in significant future growth or a scarcity premium for its specialized TCM-integrated wellness model relative to broader healthcare service providers in the Hong Kong market.
The extreme valuation multiples appear to reflect the company's micro-cap status and the unique nature of its postpartum service ecosystem rather than traditional earnings-based growth. Investors should monitor whether these multiples compress as the company attempts to scale its B2B consultancy arm, which may offer a more scalable path to earnings than its current facility-constrained model.
As reported in financial statements, MCTA maintains a gross margin of 67.19% and an operating margin of 22.32%, indicating that the firm successfully extracts high value from its specialized TCM protocols despite the significant overhead associated with its prime Causeway Bay real estate footprint.
The 22.32% operating margin suggests that the company is effectively managing its labor and occupancy costs, though this profitability is structurally tied to the physical capacity of its treatment rooms. Future margin expansion may depend on the successful transition toward higher-margin consultancy and product sales, which decouple earnings from the limitations of physical floor space.
According to recent financial disclosures, MCTA maintains a debt-to-equity ratio of 23.57%, which provides a robust buffer against interest rate volatility and supports the company's ability to navigate the high fixed-cost environment inherent in the Hong Kong medical and wellness services industry.
This conservative leverage profile appears to be a strategic choice, allowing the firm to maintain operational flexibility without the burden of significant debt service obligations. While this limits the potential for aggressive, debt-fueled expansion, it protects the company from the liquidity risks that often plague smaller, high-fixed-cost service providers during economic downturns.
The P/S ratio is frequently misapplied to MCTA, as it obscures the impact of deferred revenue from pre-paid service packages, which are common in the Hong Kong wellness sector and may significantly distort the company's true underlying cash flow and revenue recognition timing.
Analysts should instead focus on contract liabilities and deferred revenue balances to assess the health of the sales pipeline, as headline revenue may not accurately reflect the cash-generating capacity of the business. Relying solely on standard valuation multiples like P/S risks misinterpreting the company's liquidity position and the sustainability of its current service-based revenue model.
Includes 30+ ratios · 3 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MCTA stock.
Charming Medical Limited Class A Ordinary Shares's current P/E ratio is 414.5x. This places it at the 50th percentile of its historical range.
Charming Medical Limited Class A Ordinary Shares's current EV/EBITDA is 269.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Charming Medical Limited Class A Ordinary Shares's return on equity (ROE) is 2435.0%. This is above the typical threshold of 15-20% considered good for most companies.
Based on historical data, Charming Medical Limited Class A Ordinary Shares is trading at a P/E of 414.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Charming Medical Limited Class A Ordinary Shares has 67.2% gross margin and 22.3% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Charming Medical Limited Class A Ordinary Shares's Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.